Fragoulis et al. Real world study of bimekizumab demonstrates equal efficacy in IL-17i naive and exposed. @RheumNow #ACR25 Abstr#1439 https://t.co/aCcLgnKvFJ

• https://x.com/RichardPAConway/status/1982851535177707738/photo/1

Gensler et al. Bimekizumab in male and female axSpA patients. Greater benefit in males at week 16, but similar responses at week 52 @RheumNow #ACR25 Abstr#1449 https://t.co/zDYI2zItqT

• https://x.com/RichardPAConway/status/1982850528640917998/photo/1

Mac Gearailt et al. Depression in axSpA. Depression in 10%. Associated higher disease activity, worse functional status, and increased peripheral manifestations. @RheumNow #ACR25 Abstr#1409 https://t.co/8pnoQiaiQr

• https://x.com/RichardPAConway/status/1982849018951536757/photo/1

Bimekizumab showed sustained 1-year efficacy in axSpA across age, BMI, CRP, and HLA-B27 subgroups. ASAS40, ASDAS, BASDAI, ASQoL, and MRI scores improved in most groups—especially age ≤35, BMI 25–30, CRP >5, and HLA-B27+. Abstract 1451 @RheumNow #ACR25

Really useful observational study, 305 pts with TAK Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory Majority of lesions stenotic. Emphasizes importance of regular monitoring #ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym

• https://x.com/EBRheum/status/1982843733952385436/photo/1
• https://x.com/EBRheum/status/1982843733952385436/photo/1

After At-risk RA, time to discuss At-risk PsA patients ARP-PsA Prospective cohort 1400+ pts 8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology) Risk factors: Pso >15 years Pso + Family Hx US synovitis/enthesitis At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN

• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1
• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1

Mayer et al. NSAIDs in IBD. Retrospective cohort study. 250000 individuals. Non-inferiority study. No increased IBD-related hospitalisation in UC, but an increase in all-cause hospitalisation. @RheumNow #ACR25 Abstr#1434 https://t.co/he2Xmcqslk

• https://x.com/RichardPAConway/status/1982839959313662215/photo/1

Concerns using dupilumab in EGPA due to secondary eosinophilia What about when combined with IL-5 therapy? 16 pt on dupi + IL5 agent - if dupi alone caused eosinophilia -> quelled by IL-5 - no eosinophilia when dupi added to IL-5 - effective but slow @RheumNow #ACR25 Abst 1605

Don’t forget 👇 #lcSSc Pts can get and progress #ILD 1/3 of #limited #cutaneous #systemic #sclerosis #scleroderma GET ILD From #EUSTAR >14% progress Esp +Scl70 Remember to screen #CREST Pts & allow these Pts into lung disease trials #ACR25 @RheumNow @ACRheum abst#0879 https://t.co/X15tUgClzN

• https://x.com/Janetbirdope/status/1982838827770073577/photo/1
• https://x.com/Janetbirdope/status/1982838827770073577/photo/1
• https://x.com/Janetbirdope/status/1982838827770073577/photo/1

Safety & benefit of #Deucravacitinib in #SLE #LTE #PAISLEY #RCT 👇 over 4 yrs Stable response sustained over 4 yrs No new Safety signals Await Ph3 RCT results - fully enrolled #SoTyktu Abst#LB10 #ACR25 @RheumNow @ACRheum https://t.co/ZpmzOYVnq9

• https://x.com/Janetbirdope/status/1982835982748745866/photo/1

GLP1 receptors are present on cartilage, synovial and specific cells such as macrophages. Also endogenous GLP1 seemed to protect the cartilage in animal models #ACR25 @RheumNow https://t.co/ekNWbtPO4b

• https://x.com/bella_mehta/status/1982835120756453871/photo/1
• https://x.com/bella_mehta/status/1982835120756453871/photo/1

The axSpA Registry of Ireland (ASRI): 10% reported depression, w/ higher prev in older cohorts. Pts w/ depression had ⬆️peripheral involvement, ⬆️dse activity & poor functional status 💡Consider the impact of non-inflamm factors in dse burden #ACR25 @RheumNow Abs1409 https://t.co/yDfHA24M6e

• https://x.com/RHEUMarampa/status/1982834673966612660/photo/1

NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4

• https://x.com/RichardPAConway/status/1982833416073625649/photo/1

Many GLP-1 drugs in the pipeline for management in #OA #ACR25 @rheumnow https://t.co/y3UCp0CcUb

• https://x.com/bella_mehta/status/1982831363565731941/photo/1

Semaglitide did help in weight loss and decrease in pain in knee OA https://t.co/240sR5An3m #acr25 @rheumnow Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5

• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis | NEJM
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1